For the diagnosis of primary tumors, there was no statistical difference between 68Ga-MY6349 uptake and 18F-FDG uptake in NPC, HR+ BC, HER2+ BC, TNBC, esophageal cancer, NSCLC, gynecological tumors, and prostate cancer (Table 1). This evidence concerns the gene ERBB2 and breast cancer.